Outcomes and recurrence trends after skin-sparing mastectomy and immediate DIEP flap reconstruction: A single-centre analysis Authors: Mahalakshmi Ishwar, Nazia Habiba, Nagy Rizkalla, Katy Wallis, Joanna Skillman Published: 2026 ABSTRACT AbstractIntroduction: Mastectomy is indicated in 25–40% patients diagnosed with breast cancer. Skin and Nipple sparing mastectomy (SSM / NSM) are techniques that allow for the option of a single stage reconstructive procedure. DIEP flap remains the gold standard for autologous breast reconstruction with excellent aesthetic outcomes. The aim of this study was to evaluate long term results and recurrence patterns following skin sparing mastectomy and immediate reconstruction (IBR) with DIEP flap.Methods: Data were collated retrospectively for all consecutive adult patients undergoing immediate DIEP reconstruction following SSM between 1st July 2010 to 30th June 2023 for all indications at the author’s centre. Those who underwent delayed DIEP reconstruction or other methods of IBR were excluded. Primary outcome was the incidence and management of locoregional and distant recurrence(LR) and secondary outcomes included other standard oncological measures and immediate post-operative measures such as skin flap changes following SSM.Results: A total of 235 DIEP flaps in 192 patients at a mean(SD) age of 49(40–57) years were analysed. Median(SD) follow up duration was 7.2(1.4–13) years. The isolated local recurrence rate was 2.7%. LR in conjunction with distant metastasis was seen in a further 2.7% and isolated distant metastases were noted in 8.4% patients. LR occurred at a median of 2.76 (0.97–4.55) years from surgery. Isolated LR were treated with surgical resection & flap conservation followed by adjuvant chemoradiation, whereas distant metastases were treated with palliative chemoradiation as appropriate.Conclusion: IBR with DIEP following SSM remains oncologically safe with low recurrence rates. LR can be safely managed with excision and conservation of the DIEP flap.Keywords: Breast cancer, Breast reconstruction, DIEP flap, Free flap, Mastectomy, Recurrence Introduction Breast cancer is the most commonly diagnosed malignancy in women across the United kingdom.1 Although breast conservation techniques can be used for many women, mastectomy remains necessary in 25 to 40%.2,3 Immediate reconstruction can be undertaken with preservation of the skin envelope by skin sparing mastectomy (SSM) and nipple sparing mastectomy (NSM) procedures which have been noted to be oncologically sound in studies across various indications ranging from Ductal carcinoma in-situ (DCIS) to invasive cancer, with excellent long term overall survival.4,5 The use of reconstructive breast surgery has risen in the last few decades, with multiple studies showing an improvement in the quality of life, psycho-social well-being and self-esteem in patients.6,7 Immediate breast reconstruction (IBR), has the opportunity to offer women aesthetic and psychological benefits following mastectomy. More often, IBR procedures tend to be implant based rather than with purely autologous tissue following a mastectomy. Studies, however, have shown better long-term patient satisfaction with body image, stable aesthetics and overall, a better quality of life with autologous reconstruction.8 Among autologous reconstructive options, the Deep Inferior Epigastric artery Perforator (DIEP) flap has been established as the technique of choice for reconstruction due to superior long term aesthetic results and improved morbidity profile over myocutaneous reconstructive flap options (e.g. TRAM flap) by virtue of sparing the abdominal muscles.9 The DIEP flap is also preferred over loco-regional flap reconstruction and other free-flaps for breast reconstruction and is currently the most commonly performed autologous flap for breast reconstruction after mastectomy.3,8 Increasing acceptance of SSM and NSM has also facilitated the rise of IBR.10,11 IBR with DIEP offers significant advantages by being able to complete the entire surgical treatment modality in one operation.12,13 However, the structure of various surgical health services and the need for micro-surgical expertise and centralization of care, means that logistic challenges exist to the implementation of a standardized pathway for immediate DIEP reconstruction following SSM. Data on the oncological safety of immediate DIEP reconstruction, is sparse and is limited to single centre studies and registry-based studies.3,8,12,14 The increased risk of dormant tumour cells being activated by increased surgical trauma in a DIEP flap has been raised in a few previous studies.15, 16, 17 Studies on oncological safety in SSM have also focussed on singular histological entities such as DCIS or invasive ductal carcinoma.4,18, 19, 20 There is, therefore, a lack of real-world data on the oncological efficacy of immediate DIEP reconstruction following skin sparing mastectomy. The aim of the current study was to evaluate this group of patients undergoing immediate DIEP reconstruction following skin or nipple sparing mastectomy at University Hospitals of Coventry and Warwickshire and to evaluate the risk of local recurrence in these patients. Methods The data were retrospectively collated from a prospectively maintained departmental database. The data included all consecutive patients over the age of 18 years who underwent a skin sparing mastectomy and immediate autologous reconstruction with a DIEP flap at the department of plastic and reconstructive surgery at the University Hospitals of Coventry and Warwickshire, UK from 1st July 2010 to 30th June 2023. Patients undergoing other forms of breast reconstruction and delayed reconstruction were excluded from this study. Patients also undergoing other forms of resectional surgery for breast cancers were also excluded from this study. The patients were followed up until September 2024 prior to data collation. Institutional ethical clearance was not required due to the retrospective observational nature of the study. The data was collated and analysed in accordance with local trust policy and Caldicott principles. The patients were assessed at a pre-operative specialist clinic to assess suitability for DIEP reconstruction. They were also assessed by a geneticist and psychologist in case the indication was a mastectomy for reduction of future cancer risk or for aesthetic purposes on a similar background. All available investigations including radiology, biochemistry and histology (including genetic tests where applicable) were reviewed pre-operatively at the institutional multi-disciplinary meeting to formulate a management plan. Pre-operative CT angiograms of the abdomen were used as routine to assess the perforator status for each patient. The use of pre- and post-operative locoregional and systemic anti-cancer therapy (Radiotherapy and Chemotherapy) evolved over the study period, and were used in accordance with national guidance and departmental protocols at the time. They were not subject to pre-operative adjuncts such as topical Nitro-glycerine application or local heat for pre-conditioning. Operative technique The resectional and reconstructive landmarks were marked on the patient preoperatively. The skin sparing mastectomy was performed, with nipple preservation if accepted by MDT and preferred by the patient. Mastectomy scars (for example inframammary, skin reducing, peri‑areolar) were discussed with the patient and selected according to oncological principles, patients breast size, shape and preference. As a standard, the inframammary fold adherence was preserved and the mastectomy skin flap followed the mastectomy plane. After the mastectomy the homogeneity of the mastectomy flaps was checked by palpation and any excess tissue excised. In cases where the tumour was radiologically or clinically to be close to the skin or nipple, retro-areolar biopsies were taken and subcutaneous tissue sampled and sent for histological analysis. Variables and outcomes The variables analysed included demographics such as age, genetic risk status (BRCA 1 or BRCA2 positivity), laterality, the indication for mastectomy, tumour hormonal (oestrogen, progesterone and HER-2) status and the use of peri‑operative radiation or chemotherapy. The primary outcome measured in the study was the incidence and management of local and distant recurrence during the follow up period among those with a diagnosis of breast cancer. The secondary outcome measures included the post-operative incidence of skin flap changes including necrosis needing intervention, margin status of the resected specimen and the Nottingham Prognostic Index of the resected specimen. The duration of follow up was carried until September 2024, and the follow up duration was stopped if local or metastatic recurrence was noted. Data were analysed using standard statistical methods on IBM SPSS Statistics for Windows, Version 22.0. The distributions of continuous variables were tested for normality by examining the mean and standard error of skewness and the Shapiro–Wilk test. Non-parametric continuous variables were reported as the median (inter-quartile range) values, and compared with the Mann–Whitney U test. Parametric variables were presented as Mean (SD) and means were compared with ANOVA. Pearson’s correlation was used to for two continuous variables and Fisher’s exact test was used for categorical variables. Disease free survival was evaluated using KM analysis in patients with a histological diagnosis of malignancy at the time of SSM and IBR with DIEP reconstruction. A p value <0.05 was considered statistically significant for the purposes of this study. Results Demographics During the study period, a total of 547 DIEP flaps were carried out (88 bilateral) at the University Hospitals of Coventry and Warwickshire. Among these, a total of n = 235 DIEP flap procedures were carried out immediately after a skin sparing mastectomy and were eligible to be included in the study. The demographics are included in Table 1. The predominant indication for mastectomy was as the primary therapeutic procedure (n = 107 (45.5%)) where breast conservation was not possible due to the characteristics of the tumour or breast, or patient preference. The other common indications for surgery were risk reduction (n = 84 (35.7%)) and completion mastectomy for involved margins following wide local excision (n = 26 (11.1%)). There was statistically significant variation (p < 0.001) in the age across the various indications for mastectomy (Fig. 1). Table 1Demographics.Table 1: dummy alt textDemographicsTotal number of patients192Number of Bilateral reconstructions43 (18.3%)Number of right sided procedures118 (50.2%)Age (Mean (SD)) in years49 (40–57)Duration of follow up (Median (IQR)) in years7.2 (1.4–13) Demographics. Indications for SSM + IBR with DIEP flap. Cancer characteristics and pre-operative variables A total of 143 patients had a histological diagnosis of cancer. A distribution of the histological diagnoses and hormone status are collated in Table 2. A total of n = 80 patients were eligible for genetic testing for high-risk mutations predisposing to a risk of breast cancer. Among these, n = 65 (81.25%) were positive for BRCA-1 or BRCA-2 genes and one patient each were found to be positive for PALB and PALB-2 gene expression. Patients with expression of high-risk genetic mutations tended to be younger (44 (35–53) years vs. 48(39–56) years); however, this difference did not reach statistical significance (p = 0.183). Table 2Cancer characteristics.Table 2: dummy alt textCharacteristicn (%)Mean (SD) Age (y)P valueHistological diagnosis of cancer143 (60.9%)DCIS35 (14.9%)53 (48–58)0.031*Invasive ductal carcinoma76 (32.3%)48 (40–56)Invasive lobular carcinoma20 (8.5%)52 (44–60)Carcinoma other types (tubular / medullary)8 (3.4%)56 (48–64)Mixed ductal and lobular carcinoma3 (1.3%)49 (47–51)LCIS1 (0.4%)51Hormone statusER Positive84 (35.7%)51 (44–58)0.041*PR positive67 (28.5%)50 (43–57)0.708HER-2 positive30 (12.8%)49 (41–57)0.637 Cancer characteristics. A total of 77 (40.1%) patients had chemotherapy prior to the DIEP procedure and a total of 68 (35.4%) patients had prior radiotherapy treatment. Among the patients who received pre-DIEP chemotherapy, n = 29 (37.7%) received it with Neo-adjuvant intent, and the rest received it as a part of completion of breast cancer treatment following previous surgery. Patients who received chemotherapy with neoadjuvant intent were significantly younger than those who did not (46 (38–54)y vs. 53 (47–59)y; p = 0.001). Patients who received radiation were also significantly younger than those who did not (49 (41–57)y vs. 52 (45–59)y; p = 0.02). Previous surgery to the same breast had been performed in n = 76 (32.34%) cases, who, as expected, were significantly older that those who did not have previous ipsilateral breast surgery (52 (44–60)y vs. 47 (39–55)y; p < 0.001). Adjuvant chemotherapy post DIEP was used in a total of n = 48 (25%) patients. Immediate post-operative outcomes There was no immediate post-operative mortality in the study cohort. There were no cases of flap loss. The mastectomy skin flap healed in the majority of cases (71.2%). In n = 70 (29.8%) cases, there were mild issues with would healing including epidermolysis or delayed healing requiring dressings. A proactive approach was taken to any skin necrosis and n = 16 (7%) patients required debridement and among them, skin graft reconstruction was needed in n = 8 cases. The incidence of reported skin changes did not vary significantly among those with nipple sparing or sacrificing type mastectomy (36%vs 29%; p = 0.49). All cases with reported skin changes healed well within 8 weeks of post-operative follow up. Oncological outcomes The median Nottingham prognostic index score was 4.12 (2.75–5.49) in the study cohort. There was no significant correlation with age (p = 0.63). One patient with multifocal invasive ductal carcinoma was noted to have positive surgical margins at the chest wall. This patient was treated with adjuvant chemotherapy post-operatively. There were no other cases of involved margins in the 235 resected specimens. Among those with a histological diagnosis of malignancy, local recurrence was noted in n = 8 (5.5%) cases. Isolated local recurrence was noted in n = 4 (2.7%) patients, while it was diagnosed in conjunction with distant metastases in n = 4 (2.7%) cases. Isolated distant metastases were noted in a further n = 12 (8.4%) cases. Local recurrence was noted to be diagnosed at a median of 2.76 (0.97–4.55) years from surgery. Distant metastases were diagnosed at a median of 4.53 (1.50–6.86) years from surgery. Characteristics of patients with isolated locoregional recurrence were analysed further. All four patients underwent the index procedure for invasive malignancy. Three patients had invasive ductal carcinoma and one had multiple foci of high grade DCIS with one focus of invasive mucinous cancer. Two patients with IDC were BRCA2 positive, the other two were not tested. Three patients had neoadjuvant chemotherapy and none had radiation prior to the DIEP procedure. They all underwent SSM and one patient had reported skin changes post mastectomy that were managed conservatively. Risk factors for local recurrence and distant metastases were analysed among the collected variables. These are collated in Table 3. Disease free survival was analysed with Kaplan Meier analysis across Hormonal status, Genetic risk status and indications for mastectomy. None of these were found to significantly influence the disease free survival in the study cohort (Fig. 2). Table 3Variables and risk of local recurrence.Table 3: dummy alt textVariableLocal recurrenceDistant metastasesN(%)p-valueN(%)p-valueCancer Type- DCIS1 (2.85%)0.9852 (5.71%)0.823Cancer type- invasive ductal carcinoma3 (3.94%)5 (6.58%)Cancer type- invasive lobular carcinoma1 (5%)0Expression of high risk genes (BRCA / PALB)3 (4.47%)0.51510 (14.9%)0.682Hormone status ER positive4 (4.76%)14 (4.76%)0.568Hormone status PR positive3 (4.47%)13 (4.47%)0.650Hormone status HER-2 Positive3 (10%)0.0842 (6.67%)0.640Pre-operative chemotherapy4 (5.19%)0.6434 (5.19%)0.516Pre-operative radiotherapy3 (4.41%)0.974 (5.88%)0.959Nipple Sacrificing Mastectomy7 (3.34%)114 (6.67%)0.110Mastectomy Skin Flap Necrosis5 (7.1%)0.3129 (12.8%)0.063Nottingham Prognostic Index (Mann-Whitney U)0.3930.684 Variables and risk of local recurrence. DFS stratified by Hormone status, Histology and genetic status. Surgical management of recurrence Among the four patients with isolated local recurrence, none had undergone adjuvant radiotherapy; two recurrences were noted in the mastectomy skin flap, one in the axilla and one in both the skin flap and axilla. The DIEP reconstruction flap was preserved in all four cases. WLE was performed in three cases (one with axillary lymph node clearance). One patient needed skin graft following WLE. The other two underwent primary closure. One patient underwent pre-operative chemotherapy, and all four patients underwent adjuvant post-operative chemotherapy and radiotherapy after surgical treatment of the recurrence. All patients with isolated local recurrence are alive and disease free at the time of writing. Among the four patients with both loco-regional recurrence and metastatic disease, one patient underwent wire guided axillary lymph node clearance. In another, the flap was taken down as a palliative procedure, with axillary clearance, chemotherapy and radiation, and the remaining two patients received palliative chemotherapy and radiation without surgical intervention. Unfortunately, all four patients succumbed to their disease. A total of 10 patients have succumbed to the disease in the study cohort and six patients with metastatic disease are alive, on palliative treatment. One patient underwent a risk reducing mastectomy and DIEP reconstruction following two years of stability after WLE and radio-ablation of an isolated liver metastasis. She remains alive and disease free at the time of writing. This patient has not been classed as having metastatic disease for the purposes of this study. Discussion This study evaluates outcomes of immediate DIEP (deep inferior epigastric perforator) flap reconstruction following skin-sparing mastectomy (SSM) in a cohort of 235 patients. The results provide robust evidence supporting the safety and efficacy of this approach. It provides evidence for low rates of local recurrence and favourable oncological outcomes for SSM and the advantages of single stage surgery with immediate DIEP reconstruction. SSM with immediate IBR with DIEP has been subject to scrutiny over concerns of leaving residual breast tissue behind and additional implications of reactivation of dormant tumour cells. In the current study, the incidence of locoregional recurrence over a median follow up of over seven years was 5.59%. Isolated local recurrence was noted in only 2.7% cases. This is in keeping with the lower rates of recurrence with other series with SSM (3–5%) and comparable with rates of loco-regional recurrence after total / simple mastectomy.4,5,21,22 As consistently shown in previous studies, patients undergoing IBR with DIEP demonstrate an improved quality of life, higher levels of sexual wellbeing and related self-esteem and show lower levels of anxiety and depression.23, 24, 25 Mastectomy indications and demographics Indications of mastectomy were as expected in the current series with IDC and DCIS dominating the majority of cancer indications. A large proportion of patients also underwent risk reducing mastectomy. The indications for risk reduction varied across patients with previous surgery to the ipsilateral breast, deformation in the shape of the breast following previous surgery and radiation, and those with a high genetic risk of breast cancer. The last category of patients tended to be younger at surgery, and this was again reflected in the current series, although this did not reach statistical significance. The mean age of those undergoing risk reducing mastectomy was the lowest in the cohort. The emphasis on IBR is even greater in these patients.26 As mentioned before, IBR with DIEP provides the ideal reconstructive option for these with stable, sustainable long term aesthetic outcomes. It improves their QOL, psychosocial factors such as body image and confidence. IBR with DIEP therefore acts as a single stage solution for both mastectomy and reconstruction, especially in the setting of risk reduction. This also holds true for patients who have had previous treatment for breast cancer that has led to a deformity of the breast shape / contour. While, these numbers are not high in the current cohort due to various factors and the non-availability of aesthetic surgery in the NHS, some of these patients qualified for a risk reducing mastectomy as well, making SSM and IBR with DIEP as the most appropriate treatment choice.3,8 Pre-operative and post-operative characteristics Approximately one third of the current cohort had previous ipsilateral breast surgery. Close to 40% patients underwent chemotherapy and 35% patients underwent radiation therapy prior to the DIEP procedure. This is in keeping with the established multi-disciplinary treatment protocols for breast cancer.12,22,27, 28, 29 An additional 25% patients underwent adjuvant chemotherapy following DIEP. One patient with deep margin positivity following SSM and DIEP underwent adjuvant chemotherapy only. The flap was not taken down and a completion chest wall resection was not thought to be beneficial in this setting. This patient had multifocal invasive ductal carcinoma on histology and to-date, remains disease free on follow up at 12 years from surgery. There were no cases of flap loss in this cohort of patients. This serves to underline the success and robust nature of DIEP reconstruction. Mastectomy skin flap changes were reported by patients in n = 70 (29.8%) patients in the present cohort. This was defined as any patient reported changes wound over the skin flap. In the current study, only n = 16 (6.8%) presented with MSFN which needed operative intervention or vacuum assisted closure therapy for MSFN. In literature, there is widespread heterogeneity in term of the reporting of MSFN, with rates of up to 30% being reported. However, the definitions used are different across the board, from MSFN being defined as patient reported (similar to the present study), to being reported only when an operative intervention is required.30, 31, 32 On the basis of these, the rates reported in the current study are in keeping with standard reported risks in SSM / NSM cases. It is worthwhile to note that MSFN did not correlate significantly with either local recurrence or metastatic disease during the follow up period. Tang et al., in their systematic review of non-operative adjuncts for MSFN, showed significant benefits to patients who were subject to pre-operative therapy with topical nitroglycerin ointment, closed-Incision negative pressure wound therapy, topical dimethylsulfoxide ointment, oral cilostazol or local heat pre-conditioning.32 In the author’s centre, these are not used as routine interventions. They may be helpful in the setting of high risk patients for MSFN such as those with diabetes, previous radiation, obesity etc.30 In addition intraoperative ICG assessment would allow detection of poor perfusion and immediate debridement. Management of local recurrence Isolated local recurrence was managed surgically in all four patients as described in the results section. In all four cases, the recurrence was not noted to be at the chest wall level. It was in the skin flap and / or the axilla. All four cases were treated with preservation of the flap. The recurrences were noted at a median of 2.7 years from surgery, in keeping with previous literature where most recurrences are noted between 2 and 5 years after SSM. Metastatic disease, however, presented itself later in the follow up at a median of closer to five years. The prolonged DFS in metastatic disease probably represents the efficacy of the adjunctive systemic therapy rather than the mastectomy or DIEP itself. A recent series from Germany by Abdallah et al. shows similar trends in the management of local recurrence following DIEP reconstruction.33 In that series, local recurrences were managed with flap preservation and local tissue cover with care taken to preserve the flap’s vascularity. In the current series, such flaps were not needed due to the superficial location of the recurrences. Similar to the series by Abdallah et al., an MRI is the investigation of choice for patients with suspected local recurrence at the author’s centre.33 In the current series, the flap was taken down to reduce disease burden in one patient with local recurrence and concomitant distant metastases. This was combined with axillary clearance and a contra-lateral mastectomy for symmetrisation. The patient unfortunately, did succumb to the disease at eight years following mastectomy. This study represents a cohort of unselected patients undergoing IBR following SSM with DIEP flap. It’s strengths include robust parameters for reporting recurrence and disease post-operatively, a strict follow up regimen and a long duration of follow up. The study’s limitations are due to the retrospective nature of the data. The element of selection bias, however, is minimal because of the nature of the variables assessed in the current cohort i.e. local recurrence and metastatic disease. Conclusion The presented study adds to the body of evidence that reports the oncological feasibility and safety of skin sparing mastectomy and advantages of immediate breast reconstruction with a DIEP flap. The study also serves to highlight the feasibility of flap preservation in the surgical management of local recurrence. Further studies could focus on improvement of immediate peri‑operative outcomes such as pre-operative optimisation techniques, translational research into measures to analyse the mastectomy skin flap in real time for vascularity and remnant microscopic foci of malignancy. Funding None. Ethical approval Not required. Declaration of competing interest None declared Contributor Information Mahalakshmi Ishwar, Email: ml.ishwar@gmail.com. Joanna Skillman, Email: Joanna.skillman@uhcw.nhs.uk. References